Abivax to Showcase Obefazimod Data at UEG Week 2026

Abivax SA will present data on obefazimod during the United European Gastroenterology (UEG) Week 2026, held in Barcelona. The biotechnology firm focuses on developing therapeutics for chronic inflammatory diseases. At the event, the efficacy and safety of obefazimod, a drug candidate for ulcerative colitis (UC), will be detailed. The company will unveil findings from the Phase 3 ABTECT Maintenance and Induction programs, as well as long-term results from Phase 2 studies. The presentations will also cover preclinical research on the drug's anti-fibrotic activity.

CEO Marc de Garidel emphasized the importance of understanding obefazimod’s potential in treating inflammatory bowel disease. Chris Rabbat, Chief Medical Officer, highlighted the program's comprehensive data, underscoring its maturity. The presentations are slated to cover various aspects of the drug’s development, with contributions from leading experts, including insights into efficacy across patient subsets and long-term outcomes.